Medical Oncologist
Imatinib treatment timeline
How Long Does Imatinib — Take to Work?
Imatinib starts affecting your blood within weeks, but your team will not call it a response until the blood tests confirm it — and the deeper responses they are aiming for take months to establish.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Early changes are invisible — You may feel better before your blood counts shift, or the opposite — the drug is working before you feel it.
- Milestones are timed — NCCN guidelines check response at three months, six months, and twelve months. Each check is meaningful.
- Response depth matters — There are three levels — blood counts, chromosome, and molecular. Each takes longer to achieve than the last.
- Missing a target is actionable — If milestones are not met, your team has options. A suboptimal result is information, not a dead end.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Imatinib begins affecting your blood counts within the first few weeks of treatment. NCCN guidelines define response milestones at three months, six months, and twelve months, with deeper responses taking longer. Most people cannot feel the drug working at first — your team monitors through blood tests, not symptoms.
What happens in the first few weeks on imatinib?
Within the first weeks of starting imatinib, your white blood cell count and platelet count usually begin to move toward a normal range. This earliest response is tracked through a routine blood count.
You may not feel this happening. Some people feel tired or nauseous from the drug itself. Others notice an improvement in energy or a reduction in sweats as the disease burden begins to fall.
How you feel is not a reliable guide to how well the drug is working. Your blood tests will tell your team far more than your symptoms do, especially at the start.
What do the three-month and six-month checks mean?
NCCN guidelines set clear expectations for what your test results should show at the three-month and six-month marks.
By three months, your team looks at your BCR-ABL ratio — a sensitive blood test that measures how much of the abnormal gene signal remains. A meaningful fall by this point suggests the drug is working as expected.
By six months, a deeper fall is expected. If your result is not where the guidelines suggest it should be, that is the point at which your team will discuss whether to continue imatinib or consider a switch to a different drug in the same class.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What if your results are not where your team expected?
Missing a milestone does not mean treatment has failed — it means your team has information to act on.
Your oncologist may ask about adherence first, because imatinib taken inconsistently does not work consistently. They may also check for resistance mutations, which are detectable with a specific test and change the choice of next treatment.
Switching early — when a result is suboptimal rather than clearly failing — generally leads to better long-term outcomes than waiting. ESMO guidance supports acting on a suboptimal response rather than continuing to watch.
What do these terms mean?
- Hematologic response
- Your blood counts — white cells, red cells, and platelets — have returned to a normal range. This is usually the earliest response milestone and the first your team will confirm.
- Cytogenetic response
- The proportion of blood cells carrying the Philadelphia chromosome has fallen. A complete cytogenetic response means no Philadelphia-chromosome-positive cells are found by standard testing.
- Molecular response
- A more sensitive measure than cytogenetic testing, done with a PCR blood test. It detects the BCR-ABL gene signal directly. The lower the ratio, the deeper the response — major molecular response and deeper responses are what long-term stability is built on.
- BCR-ABL ratio
- The result of your PCR blood test, expressed as a percentage. It measures how much of the abnormal gene signal driving CML remains in your blood. Your team tracks this number at each milestone check.
- Treatment-free remission
- In a proportion of patients who have maintained a sustained deep molecular response over several years, stopping imatinib under close monitoring may become an option. This is discussed case by case and is not the right goal for everyone.
Did you know?
Before imatinib, the outlook for chronic-phase CML was measured in years. ASCO and ESMO now report that patients who achieve and sustain a major molecular response have life expectancy approaching that of the general population.
The milestone framework exists for a reason: catching a suboptimal response early — and switching — produces better long-term outcomes than waiting for clear failure.
Source: ASCO Educational Book; ESMO Clinical Practice Guidelines for Chronic Myeloid Leukaemia
Explore 75 more Blood Cancer Targeted Medicines topics
Drug Deep Dive: Imatinib (Gleevec)
- Adjuvant Imatinib After GIST Surgery: How Many Years?
- BCR-ABL PCR Monitoring: What 'Log Reduction' and 'MR4.5' Mean
- Can You Ever Stop Imatinib? Treatment-Free Remission Explained
- Diet and Nutrition While on Imatinib
- Fertility, Pregnancy and Contraception on Imatinib
- How Does Imatinib Work? The BCR-ABL and KIT Inhibitor Explained
- How Long Does Imatinib Take to Work?
- Imatinib (Gleevec, Veenat, Imatib): The Complete Patient Guide
- Imatinib Interactions: Paracetamol, Antacids and Herbal Medicines
- Imatinib Myths: Lifelong Dependence, Fertility and Generic Quality
- Imatinib Price in India: Brand, Generic and Monthly Cost
- Imatinib Side Effects: The Complete List and Timeline
- Imatinib Success Rate and Survival: An Honest Look at the Numbers
- Imatinib for GIST: How It Differs From CML Treatment
- Imatinib in Elderly Patients and Those With Other Illnesses
- Imatinib vs Nilotinib vs Dasatinib: Choosing a CML Drug
- Muscle Cramps and Bone Pain on Imatinib: What Actually Helps
- Nausea, Stomach Upset and Weight Gain on Imatinib
- Puffy Eyes and Swollen Legs on Imatinib: Managing Fluid Retention
- Taking Imatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Imatinib
- When Imatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Imatinib? Chronic Myeloid Leukaemia and GIST
- Will Insurance or a Government Scheme Pay for Imatinib?
- Work, Travel and Daily Life on Imatinib
Drug Deep Dive: Ibrutinib (Imbruvica)
- Diarrhoea, Joint Pain and Infection Risk on Ibrutinib
- Diet and Nutrition While on Ibrutinib
- Easy Bruising and Bleeding on Ibrutinib: What Is Normal and What Is Not
- Fertility, Pregnancy and Contraception on Ibrutinib
- How Does Ibrutinib Work? The BTK Inhibitor Explained
- How Long Does Ibrutinib Take to Work?
- How Long Will You Stay on Ibrutinib?
- Ibrutinib (Imbruvica, Ibrutix): The Complete Patient Guide
- Ibrutinib Interactions: Blood Thinners, Antifungals and Fish Oil
- Ibrutinib Myths: Lifelong Treatment, Bruising and 'It's Not Real Treatment'
- Ibrutinib Price in India: Brand, Generic and Monthly Cost
- Ibrutinib Side Effects: The Complete List and Timeline
- Ibrutinib Success Rate and Survival: An Honest Look at the Numbers
- Ibrutinib With Rituximab or Venetoclax: Continuous vs Fixed-Duration Therapy
- Ibrutinib in CLL, Mantle Cell Lymphoma and Waldenstrom's
- Ibrutinib in Elderly Patients and Those With Other Illnesses
- Ibrutinib vs Acalabrutinib vs Zanubrutinib: Comparing BTK Inhibitors
- Palpitations, Atrial Fibrillation and High Blood Pressure on Ibrutinib
- Surgery and Dental Procedures on Ibrutinib: The Bleeding Rule
- Taking Ibrutinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Ibrutinib
- When Ibrutinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Ibrutinib? CLL, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia
- Will Insurance or a Government Scheme Pay for Ibrutinib?
- Work, Travel and Daily Life on Ibrutinib
Drug Deep Dive: Rituximab (MabThera)
- Diet and Nutrition While on Rituximab
- Drug, Food and Supplement Interactions With Rituximab
- Fertility, Pregnancy and Contraception on Rituximab
- Hepatitis B Reactivation and Rituximab: The Test You Must Not Skip
- How Does Rituximab Work? The Anti-CD20 Monoclonal Antibody Explained
- How Long Does Rituximab Take to Work?
- How Long Will You Stay on Rituximab?
- Low Antibodies and Repeated Infections After Rituximab
- MabThera vs Biosimilar Rituximab in India: Cost and Equivalence
- R-CHOP and Other Rituximab Combinations Explained
- Rituximab (MabThera, Ristova and biosimilars): The Complete Patient Guide
- Rituximab Infusion Day: Premedication, Duration and What to Expect
- Rituximab Infusion Reactions: Why the First Infusion Is Different
- Rituximab Maintenance: Two More Years of Infusions, and Why
- Rituximab Myths: Vaccines, Immunity and 'Permanent Damage'
- Rituximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Rituximab Side Effects: The Complete List and Timeline
- Rituximab Success Rate and Survival: An Honest Look at the Numbers
- Rituximab in Elderly Patients and Those With Other Illnesses
- Tests and Monitoring While You Are on Rituximab
- When Rituximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Rituximab? B-Cell Lymphoma and CLL
- Why the Same Drug Treats Arthritis and Lymphoma
- Will Insurance or a Government Scheme Pay for Rituximab?
- Work, Travel and Daily Life on Rituximab
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How soon will I feel better on imatinib?
Some people notice an improvement in symptoms — less fatigue, fewer night sweats, a reduction in discomfort from an enlarged spleen — within the first few weeks. Others feel worse initially because of side effects such as nausea or tiredness from the drug itself. How quickly you feel better is not a reliable guide to how well the drug is working. Your blood test results tell your team far more than your symptoms do, especially early in treatment.
What is the BCR-ABL test and why does it matter?
BCR-ABL is the abnormal gene signal that drives CML. It forms when two chromosomes swap material incorrectly, creating what is called the Philadelphia chromosome. A PCR blood test measures how much of that signal remains in your blood. The lower the number, the deeper the response. Your team will track this ratio at each milestone check — three months, six months, twelve months — and compare it against what guidelines expect to see at each point.
Is imatinib used for conditions other than CML?
Yes. Imatinib is also used for gastrointestinal stromal tumours, known as GIST, and for some rarer conditions including certain types of leukaemia. The response timeline and the way your team monitors it will differ depending on which condition is being treated. If you have GIST, your team will explain the scan schedule and response criteria specific to that situation, which differ from the BCR-ABL milestone framework used in CML.
What happens if I miss doses?
Imatinib needs to be taken consistently every day for the levels in your blood to stay stable. Missing doses — even occasionally — can allow the BCR-ABL signal to rise again and can slow or prevent the molecular responses your team is aiming for. If cost, side effects, or anything else is making it hard to take the drug every day, tell your oncologist. There are ways to address most of those barriers, and the conversation is better to have early than after a missed milestone.
Can I stop imatinib once my results are good?
Stopping imatinib is possible for a proportion of patients who have maintained a sustained deep molecular response over a number of years. This is called treatment-free remission and it is managed under close monitoring, because the BCR-ABL signal can return. Whether you are a candidate depends on how long you have been in deep response, your specific BCR-ABL levels, and your oncologist's assessment. It is not the right goal for everyone, and the decision is always made with your treating team.
What should I tell my team at my next appointment?
Bring a note of any doses you have missed and the reason — this matters for interpreting your results honestly. Tell your team about any side effects affecting your daily life or making it hard to take the drug. Ask what your latest BCR-ABL ratio is and how it compares to the previous one. Ask which milestone is coming up next and what the target is. If your result is not where expected, ask what the next step is — your team should have a clear answer.